Amr Alaarg

Amr Alaarg

Auto-generated profile, based on publicly available information

Amr Alaarg

Department of Biomaterials Science and Technology, MIRA Institute for Biomedical Technology and Technical Medicine, University of Twente , Enschede 7522 NB, The Netherlands

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2016 in Scientific Reports
Verified
Journal Article
Open access
EWEduard Willms
Eduard Willms
HJHenrik J. Johansson
Henrik J. Johansson
IMImre Mäger
Imre Mäger
YLYi Lee
Yi Lee
KBK. Emelie M. Blomberg
K. Emelie M. Blomberg
PVPieter Vader
Pieter Vader
Cells release nano-sized membrane vesicles that are involved in intercellular communication by transferring biological information between cells. It is generally accepted that cells release at least three types of extracellular vesicles (EVs): apoptotic bodies, microvesicles and exosomes. While a wide range of putative biological functions have been attributed to exosomes, they are assumed to represent a homogenous population of EVs. We hypothesized the existence of subpopulations of exosomes with defined molecular compositions and biological properties. Density gradient centrifugation of isolated exosomes revealed the presence of two distinct subpopulations, differing in biophysical properties and their proteomic and RNA repertoires. Interestingly, the subpopulations mediated differential effects on the gene expression programmes in recipient cells. In conclusion, we demonstrate that cells release distinct exosome subpopulations with unique compositions that elicit differential effects on recipient cells. Further dissection of exosome heterogeneity will advance our understanding of exosomal biology in health and disease and accelerate the development of exosome-based diagnostics and therapeutics.

17 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
JTJun Tang
Jun Tang
SBSamantha Baxter
Samantha Baxter
AMArjun Menon
Arjun Menon
AAAmr Alaarg
Amr Alaarg
BSBrenda L. Sanchez-Gaytan
Brenda L. Sanchez-Gaytan
WMWillem J. M. Mulder
Willem J. M. Mulder
Immunological complexity in atherosclerosis warrants targeted treatment of specific inflammatory cells that aggravate the disease. With the initiation of large phase III trials investigating immunomodulatory drugs for atherosclerosis, cardiovascular disease treatment enters a new era. We here propose a radically different approach: implementing and evaluating in vivo a combinatorial library of nanoparticles with distinct physiochemical properties and differential immune cell specificities. The library’s nanoparticles are based on endogenous high-density lipoprotein, which can preferentially deliver therapeutic compounds to pathological macrophages in atherosclerosis. Using the apolipoprotein E-deficient (Apoe−/−) mouse model of atherosclerosis, we quantitatively evaluated the library’s immune cell specificity by combining immunological techniques and in vivo positron emission tomography imaging. Based on this screen, we formulated a liver X receptor agonist (GW3965) and abolished its liver toxicity while still preserving its therapeutic function. Screening the immune cell specificity of nanoparticles can be used to develop tailored therapies for atherosclerosis and other inflammatory diseases. Significance The immune system plays an essential role in the pathophysiology of major diseases such as atherosclerosis, diabetes, and cancer, which has inspired the development of numerous small molecules to modulate immune cells, intending to create immunotherapies for these diseases. Tissue- and cell-specific delivery of these small molecules is the key to transform these compounds to safe, potent immunotherapies. In this study, we present an in vivo nanoparticle screen approach that involves designing and evaluating a library of nanoparticles with distinct immune cell targeting specificity. This study carries out a systematic in vivo immune cell screening to create effective nanoparticle-based immunotherapy for modulating the pathological immune cells in atherosclerosis.

1 January 2013 in Frontiers in Physiology
Verified
Journal Article
Open access
AAAmr Alaarg
Amr Alaarg
RSRaymond Schiffelers
Raymond Schiffelers
WSWouter van Solinge
Wouter van Solinge
RWRichard van Wijk
Richard van Wijk
Hereditary hemolytic anemia encompasses a heterogeneous group of anemias characterised by decreased red blood cell survival because of inherited membrane, enzyme, or hemoglobin disorders. Affected red blood cells are more fragile, less deformable, and more susceptible to shear stress and oxidative damage, and show increased vesiculation. Red blood cells, as essentially all cells, constitutively release phospholipid extracellular vesicles in vivo and in vitro in a process known as vesiculation. These extracellular vesicles comprise a heterogeneous group of vesicles of different sizes and intracellular origins. They are described in literature as exosomes if they originate from multi-vesicular bodies, or as microvesicles when formed by a one-step budding process directly from the plasma membrane. Extracellular vesicles contain a multitude of bioactive molecules that are implicated in intercellular communication and in different biological and pathophysiological processes. Mature red blood cells release in principle only microvesicles. In hereditary hemolytic anemias, the underlying molecular defect affects and determines red blood cell vesiculation, resulting in shedding microvesicles of different compositions and concentrations. Despite extensive research into red blood cell biochemistry and physiology, little is known about red cell deformability and vesiculation in hereditary hemolytic anemias, and the associated pathophysiological role is incompletely asessed. In this review, we discuss recent progress in understanding extracellular vesicles biology, with focus on red blood cell vesiculation. Also, we review recent scientific findings on the molecular defects of hereditary hemolytic anemias, and their correlation with red blood cell deformability and vesiculation. Integrating bio-analytical findings on abnormalities of red blood cells and their microvesicles will be critical for a better understanding of the pathophysiology of hereditary hemolytic anemias.

1 October 2016 in International Journal of Nanomedicine
Verified
Journal Article
Open access
PDF file
AAAmr Alaarg
Amr Alaarg
NJNan Yeun Jordan
Nan Yeun Jordan
JVJohan Jf Verhoef
Johan Jf Verhoef
JMJosbert M Metselaar
Josbert M Metselaar
GSGert Storm
Gert Storm
RKRobbert Kok
Robbert Kok
Inflammation, oxidative stress, and uncontrolled cell proliferation are common key features of chronic inflammatory diseases, such as atherosclerosis and cancer. ω3 polyunsaturated fatty acids (PUFAs; also known as omega3 fatty acids or fish oil) have beneficial effects against inflammation upon dietary consumption. However, these effects cannot be fully exploited unless diets are enriched with high concentrations of fish oil supplements over long periods of time. Here, a nanomedicine-based approach is presented for delivering effective levels of PUFAs to inflammatory cells. Nanoparticles are internalized by immune cells, and hence can adequately deliver bioactive lipids into these target cells. The ω3 FA docosahexaenoic acid was formulated into liposomes (ω-liposomes), and evaluated for anti-inflammatory effects in different types of immune cells. ω-Liposomes strongly inhibited the release of reactive oxygen species and reactive nitrogen species from human neutrophils and murine macrophages, and also inhibited the production of the proinflammatory cytokines TNFα and MCP1. Moreover, ω-liposomes inhibited tumor-cell proliferation when evaluated in FaDu head and neck squamous carcinoma and 4T1 breast cancer cells in in vitro cultures. We propose that ω-liposomes are a promising nanonutraceutical formulation for intravenous delivery of fish oil FAs, which may be beneficial in the treatment of inflammatory disorders and cancer.

23 January 2017 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
PDF file
BSBrenda Sanchez-Gaytan
Brenda Sanchez-Gaytan
FFFrançois Fay
François Fay
SHSjoerd Hak
Sjoerd Hak
AAAmr Alaarg
Amr Alaarg
ZFZahi A. Fayad
Zahi A. Fayad
YZYiming Zhao
Yiming Zhao

1 August 2016 in Nanomedicine: Nanotechnology, Biology and Medicine
Verified
Journal Article
Closed access
FVFleur M. van der Valk
Fleur M. van der Valk
DSDominik M Schulte
Dominik M Schulte
SMSvenja Meiler
Svenja Meiler
JTJun Tang
Jun Tang
KZKang He Zheng
Kang He Zheng
AHAnouk A.J. Hamers
Anouk A.J. Hamers